Silexion Therapeutics Corp
SLXN evidence brief
What we can confirm
- BioSniper Score:
- 4.4 / 10
- Market Cap:
- $2.0M
- Cash Runway:
- 2.3 mo
What it means
What to watch
Prepared research question
What matters most for SLXN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SLXN
Silexion Therapeutics Corp (SLXN) is a clinical-stage biotechnology company developing RNA interference (RNAi) therapies for KRAS-driven cancers, with its lead candidate SIL204 now in a Phase 2/3 trial for locally advanced pancreatic cancer.
Key risk: Cash runway risk
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for Silexion Therapeutics Corp.
Silexion Therapeutics Corp (SLXN) is a clinical-stage biotechnology company developing RNA interference (RNAi) therapies for KRAS-driven cancers, with its lead candidate SIL204 now in a Phase 2/3 trial for locally advanced pancreatic cancer.
- Lead candidate SIL204 is in a global Phase 2/3 trial for locally advanced pancreatic cancer, with first patient dosed in September 2026 [news · 2026-09-30].
- Cash & equivalents were $2.2M as of 2026-06-30, with a net loss of $3.6M and zero shareholders' equity [sec].
- The company raised over $9 million in Q3 2025 to strengthen its balance sheet [news · 2025-11-12].
- SIL204 has shown preclinical activity across eight KRAS mutations and four cancer types, including pancreatic, colorectal, lung, and gastric cancer [news · 2026-03-17].
- Regulatory approvals for the Phase 2/3 trial were obtained from the Israeli Ministry of Health and Germany's BfArM in early 2026 [news · 2026-03-24][news · 2026-04-28].
What works
- SIL204 has demonstrated broad preclinical activity across multiple KRAS mutations and cancer types, suggesting a wide therapeutic potential [news · 2026-03-17].
- The company successfully transitioned from regulatory preparation to active clinical execution, with the Phase 2/3 trial initiated at a leading academic medical center [news · 2026-07-29].
- Silexion secured regulatory approvals from both Israel and Germany, enabling a multinational clinical program [news · 2026-03-24][news · 2026-04-28].
What to weigh
- The company has very limited cash ($2.2M as of 2026-06-30) and zero shareholders' equity, indicating a precarious financial position [sec].
- Silexion reported a net loss of $3.6M for the period ending 2026-06-30, with no revenue mentioned in the available data [sec].
- The Phase 2/3 trial is still in early stages (first patient dosed in September 2026), so efficacy and safety data are not yet available [news · 2026-09-30].
From the filings
Quoted directly from source documents.
First patient dosed in Phase 2/3 trial of SIL204
“Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer”
News · September 30, 2026
Preclinical activity across eight KRAS mutations and four cancer types
“significant positive preclinical findings for SIL204 across eight KRAS mutations and four cancer types, including first evidence of activity in gastric cancer”
News · March 17, 2026
Regulatory approval from Israeli Ministry of Health
“Israeli Ministry of Health approved the initiation of Silexion's Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer”
News · May 18, 2026
Risks & what to watch (3)›
Key risks
- Cash runway risk — With only $2.2M cash as of 2026-06-30 and ongoing losses, the company may need near-term financing to continue operations [sec].
- Clinical execution risk — The Phase 2/3 trial has just begun; no efficacy or safety data are yet available, and clinical failure is a possibility [news · 2026-09-30].
- Zero shareholders' equity — Shareholders' equity of $0.0M as of 2026-06-30 indicates the company may be technically insolvent or deeply in debt [sec].
What to watch
- Interim or final data from the Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer [news · 2026-09-30].
- Any new financing or capital raise announcements given the low cash balance [sec].
- Expansion of the SIL204 program into additional KRAS-driven cancer types or combination regimens [news · 2026-08-14].
- Regulatory updates or clinical holds from Israeli or German authorities [news · 2026-05-18].
Sources: News · Generated October 2, 2026 · How we verify sources →
Run Silexion Therapeutics Corp through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Silexion Therapeutics Corp facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
2.3 months
D/E 95.50 · 0% dilution
Lead: Phase 2/Phase 3
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
7
Total value held
$47K
| Holder | Shares | Value |
|---|---|---|
| citadel advisors llc | 20,926 | $27K |
| two sigma securities, llc | 11,657 | $15K |
| montag a & associates inc | 3,000 | $4K |
| ubs group ag | 517 | $662 |
| pflug koory, llc | 333 | $426 |
| jones financial companies lllp | 26 | $32 |
| sbi securities co., ltd. | 20 | $26 |
Short Interest
as of May 22, 2026- % of float
- 1.0%
- Days to cover
- 0.3
- Shares short
- 33,126
- Daily short volume (May 8, 2026)
- 61.9%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SLXN short interestFrequently asked questions
What is the AI investment thesis for Silexion Therapeutics Corp?
Silexion Therapeutics Corp (SLXN) is a clinical-stage biotechnology company developing RNA interference (RNAi) therapies for KRAS-driven cancers, with its lead candidate SIL204 now in a Phase 2/3 trial for locally advanced pancreatic cancer.
What is Silexion Therapeutics Corp's lead drug candidate?
Silexion Therapeutics Corp's most advanced tracked candidate is sil204 (Phase 2/Phase 3) for Non-resectable locally advanced pancreatic cancer (LAPC) with KRAS G12D/V mutations.
Who is the CEO of Silexion Therapeutics Corp?
Mr. Ilan Hadar M.B.A. is the chief executive officer of Silexion Therapeutics Corp (SLXN).
Where is Silexion Therapeutics Corp headquartered?
Silexion Therapeutics Corp (SLXN) is headquartered in Jerusalem, Israel.
What therapeutic areas does Silexion Therapeutics Corp focus on?
Silexion Therapeutics Corp develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.